(RTTNews) - Acumen Pharmaceuticals Inc's (ABOS) INTERCEPT-AD data has been published in the Journal of Prevention of Alzheimer's Disease.
INTERCEPT-AD was a phase I trial that evaluated the company's investigational drug, Sabirnetug, for the treatment of early Alzheimer's disease.
Sabirnetug, formerly known as ACU193, is a monoclonal antibody that selectively targets amyloid ß oligomers, a highly toxic form of Aß that accumulates early in Alzheimer's disease.
The topline results from the INTERCEPT-AD trial were reported in July 2023.
According to the findings, the study met primary and secondary objectives, demonstrating proof-of-mechanism for Sabirnetug. There was a rapid, dose-related, statistically significant amyloid plaque reduction within higher dose multiple-ascending dose cohorts. Additionally, the study observed low overall levels of amyloid-related imaging abnormalities (ARIA), including edema/effusion (ARIA-E) and hemorrhage/hemosiderin deposition (ARIA-H).
Daniel O'Connell, Chief Executive Officer of Acumen, said, "The publication of this data in the Journal of Prevention of Alzheimer's Disease is a significant milestone in our ongoing clinical development of sabirnetug, and reflects our commitment to advancing the collective understanding about the underlying pathology of Alzheimer's disease and developing a next-generation treatment for this burdensome disease."
A phase II, multi-center, placebo-controlled clinical trial evaluating Sabirnetug in patients with early Alzheimer's disease, dubbed ALTITUDE-AD, is underway.
The ALTITUDE-AD study, designed to enrol 540 adults ages 50 to 90 years, dosed the first patient in May 2024, with enrollment completion expected in the first half of this year.
As of Sept. 30, 2024, the company had cash, cash equivalents and marketable securities of $258.9 million, which is expected to support current clinical and operational activities into the first half of 2027.
ABOS closed Wednesday's (Jan. 08, 2025) trading at $1.70, down 7.10%. In Premarket trading Friday, the stock is up 18.24% at $2.01.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.